Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 4:16:11795549221139357.
doi: 10.1177/11795549221139357. eCollection 2022.

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase

Binoy Yohanan  1 , Binsah George  1
Affiliations
Review

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase

Binoy Yohanan et al. Clin Med Insights Oncol. .

Abstract

Despite the major advancements in the management of chronic phase (CP) chronic myeloid leukemia (CML), blast crisis (BC) remains a major therapeutic challenge. BC can be myeloid, lymphoid, or mixed lineage with myeloid BC being the most common type. BC in CML is mediated by aberrant tyrosine kinase activity of the BCR::ABL fusion protein. The introduction of BCR::ABL tyrosine kinase inhibitor (TKI) has been a gamechanger in the treatment of CML and there has been a significant reduction in the incidence of BC. The main treatment goal in BC is to achieve a second CP and consolidate that with an allogeneic stem cell transplantation (SCT) in eligible patients. The outcomes in BC remain dismal even in the current era. In this review, we provide an overview of the biology and current therapeutic approach in myeloid BC.

Keywords: Chronic myeloid leukemia; additional chromosomal abnormality; blast crisis; stem cell transplant; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Algorithm for TKI selection in CP-CML. CML indicates chronic myeloid leukemia; CP, chronic phase; TKI, tyrosine kinase inhibitor.
Figure 2.
Figure 2.
Optimal milestones in CML-CP therapy. CML indicates chronic myeloid leukemia; CP, chronic phase.
Figure 3.
Figure 3.
Current management in CML myeloid BC. BC indicates blast crisis; CML, chronic myeloid leukemia; CP, chronic phase; HMA, hypomethylating agent; SCT, stem cell transplantation; TKI, tyrosine kinase inhibitor; FLAG-IDA, fludarabine,cytarabine,granulocyte colony stimulating factor (G-CSF), idarubicin.
See this image and copyright information in PMC

References

    1. Kantarjian HM, Keating MJ, Talpaz M, et al.. Chronic myelogenous leukemia in blast crisis. Am J Med. 1987;83:445-454. doi:10.1016/0002-9343(87)90754-6. - DOI - PubMed
    1. Druker BJ, Guilhot F, O’Brien SG, et al.. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. doi:10.1056/NEJMoa062867. - DOI - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-2390. - PMC - PubMed
    1. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94. doi:10.1159/000046636. - DOI - PubMed
    1. Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94:S107-S121. doi:10.1007/s00277-015-2325-z. - DOI - PubMed